CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Labopharm Inc. (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Labopharm Inc. (USA)
102, 6111 av. Royalmount
Phone: (450) 686-1017p:450 686-1017 MONTREAL, QC  H4P2T4  Canada Fax: (450) 686-9141f:450 686-9141

This company ceased filing statements with the SEC on 7/12/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Labopharm Inc. is an international, specialty pharmaceutical company focused on optimizing the performance of existing drugs by incorporating its advanced controlled-release technologies. The Company’s lead product, a once-daily formulation of the analgesic tramadol, is being commercialized internationally and it focuses to pursue additional launches in markets around the world. Its second product, OLEPTRO, a once-daily formulation of trazodone (a serotonin antagonist reuptake inhibitor) for the treatment of major depressive disorder (MDD) has received regulatory approval from the United States Food and Drug Administration (FDA) and is in the process of finalizing the commercialization plan for its product. It is also developing a series of abuse- and misuse-deterrent products based on its Contramid-based technology platform. In addition, it has other products in development utilizing its Contramid or its polymeric nano-delivery system (PNDS) technologies.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201112/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Santo J.Costa 66 5/4/2006 3/2/2006
President, Chief Executive Officer, Non-Independent Director Mark A.D'Souza 3/22/2011 10/1/2006
Chief Financial Officer SylvainGuenette 3/22/2011 1/1/2009
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Labopharm Cyprus Limited
Labopharm Europe Limited
Labopharm USA, Inc.

General Information
Outstanding Shares: 71,571,641 (As of 8/30/2011)
Stock Exchange: OTC
Fax Number: (450) 686-9141


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023